# Globus Medical (GMED) — Earnings

GMED · NYSE · Stock

Canonical page: https://www.lighthorse.io/tickers/gmed/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | $1.34 |
| EPS estimate | $1.10 |
| EPS surprise | +21.92% |
| Revenue surprise | +0.86% |
| Revenue | $789.6M |
| Revenue estimate | $782.9M |
| Reported | Aug 6, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1237831/000162828026054450/gmed-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/c917e0ef-28a8-3b4e-0bcc-dd28cfb12901.html) |

Globus Medical reported Q2 2026 results on August 6, 2026. Earnings per share were $1.34, ahead of the $1.10 estimate by 21.92% and the highest in the table. Revenue was $789.6 million, 0.86% above the $782.9 million consensus. Compared with Q2 2025, EPS rose about 56% from $0.86 and revenue rose about 5.9% from $745.3 million.

Annual EPS grew from $2.07 in 2022 to $2.33 in 2023, $3.14 in 2024 and $4.00 in 2025. The first half of 2026 adds up to $2.46 per share, about 60% more than the $1.54 of the first half of 2025. Quarterly revenue stepped up from $383.6 million in Q3 2023 to $616.5 million in Q4 2023 and has stayed at $598 million or more since, peaking at $826.4 million in Q4 2025. Globus Medical beat the EPS estimate 17 times. Its largest beat was 51.13% in Q3 2025.

The company reported its third quarter between November 4 and November 8 in each of the past five years. That points to early November 2026 for the Q3 2026 report. It will show how results compare with Q3 2025's $1.18 per share and $769.0 million in revenue.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 6, 2026 | $1.10 | $1.34 | 21.92% | $782.9M | $789.6M |
| Q1 2026 | May 7, 2026 | $0.92 | $1.12 | 21.81% | $740.3M | $759.9M |
| Q4 2025 | Feb 24, 2026 | $1.13 | $1.28 | 12.88% | $801.7M | $826.4M |
| Q3 2025 | Nov 6, 2025 | $0.78 | $1.18 | 51.13% | $734.7M | $769.0M |
| Q2 2025 | Aug 7, 2025 | $0.75 | $0.86 | 14.19% | $741.1M | $745.3M |
| Q1 2025 | May 8, 2025 | $0.74 | $0.68 | -8.60% | $625.9M | $598.1M |
| Q4 2024 | Feb 20, 2025 | $0.75 | $0.84 | 12.36% | $645.7M | $657.3M |
| Q3 2024 | Nov 5, 2024 | $0.65 | $0.83 | 28.26% | $604.7M | $625.7M |
| Q2 2024 | Aug 6, 2024 | $0.68 | $0.75 | 10.72% | $615.3M | $629.7M |
| Q1 2024 | May 7, 2024 | $0.57 | $0.72 | 26.98% | $586.8M | $606.7M |
| Q4 2023 | Feb 20, 2024 | $0.58 | $0.60 | 2.70% | $608.8M | $616.5M |
| Q3 2023 | Nov 7, 2023 | $0.54 | $0.57 | 5.58% | $306.8M | $383.6M |
| Q2 2023 | Aug 3, 2023 | $0.59 | $0.63 | 6.67% | $279.5M | $291.6M |
| Q1 2023 | May 4, 2023 | $0.51 | $0.53 | 4.19% | $253.7M | $276.7M |
| Q4 2022 | Feb 21, 2023 | $0.56 | $0.59 | 5.39% | $276.7M | $274.5M |
| Q3 2022 | Nov 8, 2022 | $0.52 | $0.50 | -3.42% | $253.4M | $254.1M |
| Q2 2022 | Aug 4, 2022 | $0.53 | $0.56 | 4.97% | $259.4M | $263.6M |
| Q1 2022 | May 10, 2022 | $0.47 | $0.42 | -10.20% | $233.9M | $230.5M |
| Q4 2021 | Feb 17, 2022 | $0.47 | $0.49 | 3.73% | $243.5M | $250.0M |
| Q3 2021 | Nov 4, 2021 | $0.45 | $0.50 | 10.72% | $228.3M | $229.7M |

## Frequently Asked Questions

### When did Globus Medical (GMED) last report earnings?

Globus Medical last reported on Aug 6, 2026, covering fiscal Q2 2026.

### Did GMED beat earnings estimates?

Yes. Globus Medical reported EPS of $1.34 for Q2 2026 against a $1.10 estimate — a 21.92% beat.

### How much revenue did GMED report last quarter?

Globus Medical reported $789.6M in revenue for Q2 2026, against a consensus estimate of $782.9M.

## Similar Stocks

- [WST](https://www.lighthorse.io/tickers/wst) — West Pharmaceutical Services, Inc. Common Stock
- [VCYT](https://www.lighthorse.io/tickers/vcyt) — Veracyte, Inc. - Common Stock

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).